A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
61actual
Sites
17
Countries
Germany, Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-14 | actual | When the study began enrolling |
| Primary completion | 2025-12-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-05 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Facial Volume Deficit
Intervention
- Device: HAC 22L
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving "Responder" Status Based on the Evaluating Investigator's (EI) live assessment of Mid-Face Volume Deficit Scale (MFVDS)
measured Month 6
Number of Participants with Adverse Events
measured Up to approximately 25 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed